The DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.
Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer
Open accessPublished version of a preprint
Abstract
Mutations in RAS proteins occur widely in human cancer. Prompted by the confirmation of KRAS mutation as a predictive biomarker of response to epidermal growth factor receptor (EGFR)–targeted therapies, limited clinical testing for RAS pathway mutations has recently been adopted. We performed a multiplatform genomic analysis to characterize, in a nonbiased manner, the biological, biochemical, and prognostic significance of Ras pathway alterations in colorectal tumors and other solid tumor malignancies. Mutations in exon 4 of KRAS were found to occur commonly and to predict for a more favorable clinical outcome in patients with colorectal cancer. Exon 4 KRAS mutations, all of which were identified at amino acid residues K117 and A146, were associated with lower levels of GTP-bound RAS in isogenic models. These same mutations were also often accompanied by conversion to homozygosity and increased gene copy number, in human tumors and tumor cell lines. Models harboring exon 4 KRAS mutations exhibited mitogen-activated protein/extracellular signal-regulated kinase kinase dependence and resistance to EGFR-targeted agents. Our findings suggest that RAS mutation is not a binary variable in tumors, and that the diversity in mutant alleles and variability in gene copy number may also contribute to the heterogeneity of clinical outcomes observed in cancer patients. These results also provide a rationale for broader KRAS testing beyond the most common hotspot alleles in exons 2 and 3. Cancer Res; 70(14); 5901–11. ©2010 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“146 mutations do not alter the rate of GTP hydrolysis, but cause hyperactivation through an increased rate of GDP exchange4,10–12”
From The origins and genetic interactions of KRAS mutations are allele- and tissue-specific (2021) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
The International HapMap Project
†The International HapMap Consortium, Genotyping centres: Baylor College of Medicine and ParAllele BioScience, Gibbs, R. A., Belmont, J. W., Hardenbol, P., Willis, T. D., Yu, F., Chinese HapMap Consortium, Yang, H., Ch'ang, L.-Y., et al. (2003) · Nature · doi:10.1038/nature02168 · Cited by 6,057
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Self-citationKRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
Proteins regulating Ras and its relatives
Boguski, M. S., & McCormick, F. P. (1993) · Nature · doi:10.1038/366643a0 · Cited by 1,905
RAS oncogenes: the first 30 years
Malumbres, M., & Barbacid, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1097 · Cited by 1,902 · cited 1×
“Constitutive mitogen-activated protein kinase (MAPK) activation is frequent in human cancer and is often the result of activating mutations in RAS (1, 2).”
BackgroundWild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591 · cited 1×
“Our analysis suggests that a broader assessment of RAS mutations beyond the most common mutations in exon 2 is warranted and would lead to the identification of a mutation predicted to confer EGFR inhibitor resistance in close to 50% of patients with colorectal cancer (12, 19).”
Background
Cited by
Sorted by citations
Items 101–200 of 289
Endometrial Carcinomas With Clear Cells
Han, G., Soslow, R. A., Wethington, S. L., Levine, D. A., Bogomolniy, F., Clement, P. B., Köbel, M., Gilks, C. B., & DeLair, D. F. (2015) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000162 · Cited by 56
Self-citationDeng, L., Kiedrowski, L. A., Ravera, E., Cheng, H., & Halmos, B. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.007 · Cited by 56
Adjuvant FOLFOX +/− cetuximab in fullRAS andBRAF wildtype stage III colon cancer patients
Taı̈eb, J., Balogoun, R., Malicot, K. L., Tabernero, J. M., Mini, E., Folprecht, G., Laethem, J. V., Emile, J.-F., Mulot, C., Fratté, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw687 · Cited by 54
Frankel, T. L., Vakiani, E., Nathan, H., DeMatteo, R. P., Kingham, T. P., Allen, P. J., Jarnagin, W. R., Kemeny, N. E., Solit, D. B., & D'Angelica, M. I. (2016) · Cancer · doi:10.1002/cncr.30351 · Cited by 50
Self-citationAhn, D. H., Barzi, A., Ridinger, M., Samuëlsz, E., Subramanian, R. A., Wu, C.-C., Croucher, P. J. P., Smeal, T., Kabbinavar, F. F., & Lenz, H.-J. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3053 · Cited by 49
Synergistic Effects of Combined Wnt/KRAS Inhibition in Colorectal Cancer Cells
Mologni, L., Brussolo, S., Ceccon, M., & Gambacorti-Passerini, C. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051449 · Cited by 50
Guedes, J. G., Veiga, I., Rocha, P., Pinto, P., Pinto, C., Pinheiro, M., Peixoto, A., Fragoso, M., Raimundo, A. C., Ferreira, P., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-169 · Cited by 48
PTPN11 Plays Oncogenic Roles and Is a Therapeutic Target for BRAF Wild-Type Melanomas
Hill, K. S., Roberts, E. R., Wang, X., Marin, E. M., Park, T. D., Son, S., Ren, Y., Fang, B., Yoder, S., Kim, S., et al. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0777 · Cited by 47
MicroRNA-425-5p Expression Affects BRAF/RAS/MAPK Pathways In Colorectal Cancers
Angius, A., Pira, G., Scanu, A. M., Uva, P., Sotgiu, G., Saderi, L., Manca, A., Serra, C., Uleri, E., Piu, C., et al. (2019) · International Journal of Medical Sciences · doi:10.7150/ijms.35269 · Cited by 44
Radiomics and Radiogenomics in Evaluation of Colorectal Cancer Liver Metastasis
Wang, Y., Ma, L., Yin, X., & Gao, B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.689509 · Cited by 45
Fury, M. G., Sherman, E. J., Ho, A. L., Xiao, H., Tsai, F. Y.-C., Nwankwo, O., Sima, C. S., Heguy, A., Katabi, N., Haque, S. S., et al. (2013) · Cancer · doi:10.1002/cncr.27986 · Cited by 43
Self-citationRankin, A., Klempner, S. J., Erlich, R., Sun, J. X., Grothey, A., Fakih, M., George, T. J., Lee, J., Ross, J. S., Stephens, P. J., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0148 · Cited by 40
Clinical cancer genomics: how soon is now?
Taylor, B. S., & Ladanyi, M. (2010) · The Journal of Pathology · doi:10.1002/path.2794 · Cited by 41
Self-citationJones, R. P., Brudvik, K. W., Franklin, J. M., & Poston, G. J. (2017) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2017.02.014 · Cited by 40
Hsu, H., Lapke, N., Wang, C., Lin, P.-Y., You, J. F., Yeh, C. Y., Tsai, W., Hung, H., Chiang, S.-F., Chen, H., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1306 · Cited by 38
RAS Mutations as Predictive Biomarkers in Clinical Management of Metastatic Colorectal Cancer
Waring, P. M., Tie, J., Maru, D. M., & Karapetis, C. S. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2015.10.006 · Cited by 41
Colorectal Cancers from Distinct Ancestral Populations Show Variations in BRAF Mutation Frequency
Hanna, M., Go, C. K., Roden, C., Jones, R. T., Pochanard, P., Javed, A. Y., Javed, A., Mondal, C., Palescandolo, E., Hummelen, P. V., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074950 · Cited by 37
Colorectal cancer in Chinese patients: current and emerging treatment options
Ma, B. B. Y., & Li, L. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s48409 · Cited by 36
Radiologic response to MEK inhibition in a patient with a WNT‐activated craniopharyngioma
Patel, K., Allen, J. C., Zagzag, D., Wisoff, J. H., Radmanesh, A., Gindin, T. S., & Nicolaides, T. P. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28753 · Cited by 34
Divergent Mechanisms Activating RAS and Small GTPases Through Post-translational Modification
Osaka, N., Hirota, Y., Ito, D., Ikeda, Y., Kamata, R., Fujii, Y., Chirasani, V. R., Campbell, S. L., Takeuchi, K., Senda, T., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.707439 · Cited by 35
Targeting MEK in vemurafenib-resistant hairy cell leukemia
Caeser, R., Collord, G., Yao, W., Chen, Z., Vassiliou, G. S., Beer, P. A., Du, M., Scott, M. A., Follows, G., & Hodson, D. J. (2018) · Leukemia · doi:10.1038/s41375-018-0270-2 · Cited by 32
Fransson, S. M., Martinez‐Monleon, A., Johansson, M., Sjöberg, R., Björklund, C., Ljungman, G., Ek, T., Kogner, P., & Martinsson, T. (2020) · Scientific Reports · doi:10.1038/s41598-020-78370-7 · Cited by 33
Epidermal Growth Factor Receptor Pathway Mutations and Colorectal Cancer Therapy
Grossmann, A. H., & Samowitz, W. S. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2011-0047-ra · Cited by 33
Atreya, C. E., Yaeger, R., & Chu, E. (2017) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_175679 · Cited by 35
Belardinilli, F., Capalbo, C., Buffone, A., Petroni, M., Colicchia, V., Ferraro, S., Zani, M., Nicolussi, A., D'inzeo, S., Coppa, A., et al. (2015) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2015.04.003 · Cited by 32
Yoshida, Y., Tsunoda, T., Doi, K., Fujimoto, T., Tanaka, Y., Ota, T., Ogawa, M., Matsuzaki, H., Kuroki, M., Iwasaki, A., et al. (2012) · PubMed · Cited by 32
Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas
Tone, A. A., McConechy, M. K., Yang, W., Ding, J., Yip, S. S. F., Kong, E., Wong, K., Gershenson, D. M., MacKay, H. J., Shah, S. P., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-982 · Cited by 31
KRAS, BRAF, and TP53 Deep Sequencing for Colorectal Carcinoma Patient Diagnostics
Rechsteiner, M., von Teichman, A., Rüschoff, J. H., Fankhauser, N., Pestalozzi, B. C., Schraml, P., Weber, A., Wild, P. J., Zimmermann, D. R., & Moch, H. (2013) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.02.001 · Cited by 30
koochak, A., Rakhshani, N., Niya, M. H. K., Tameshkel, F. S., Sohrabi, M., Babaee, M. R., Rezvani, H., Bahar, B., Imanzade, F., Zamani, F., et al. (2016) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2016.17.2.603 · Cited by 30
Shen, M., Qi, R., Ren, J., Lv, D., & Yang, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.780655 · Cited by 31
Kaczirek, K., Ciuleanu, T., Vrbanec, D., Márton, E., Messinger, D., Liegl‐Atzwanger, B., Wrba, F., Knittelfelder, R., Lindner, E., Zielinski, C. C., et al. (2014) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2014.12.003 · Cited by 29
Mechanistic Differences of Activation of Rac1 P29S and Rac1 A159V
Senyuz, S., Jang, H., Nussinov, R., Keskin, Ö., & Gürsoy, A. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.1c00883 · Cited by 29
Somatic DNA mutation analysis in targeted therapy of solid tumours.
Yu, B., O'Toole, S. A., & Trent, R. J. (2015) · PubMed Central · doi:10.3978/j.issn.2224-4336.2015.04.04 · Cited by 29
Extended RAS testing in metastatic colorectal cancer-Refining the predictive molecular biomarkers.
Al-Shamsi, H. O., Alhazzani, W. A., & Wolff, R. A. (2015) · PubMed Central · doi:10.3978/j.issn.2078-6891.2015.016 · Cited by 28
Lavacchi, D., Fancelli, S., Roviello, G., Castiglione, F., Caliman, E., Rossi, G., Venturini, J., Pellegrini, E., Brugia, M., Vannini, A., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1055019 · Cited by 29
Leichsenring, J., Stögbauer, F., Volckmar, A., Buchhalter, I., de Oliveira, C. M. M., Kirchner, M., Fröhling, S., Hassel, J. C., Enk, A. H., Schirmacher, P., et al. (2018) · Pathology · doi:10.1016/j.pathol.2018.08.004 · Cited by 25
The HER family as therapeutic targets in colorectal cancer
Ye, P., Wang, Y., Li, R., Chen, W., Wan, L., & Cai, P. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103681 · Cited by 27
Panitumumab in Metastatic Colorectal Cancer: The Importance of Tumour RAS Status
Peeters, M., Karthaus, M., Rivera, F., Terwey, J.-H., & Douillard, J. (2015) · Drugs · doi:10.1007/s40265-015-0386-x · Cited by 23
Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer
Lee, S., & Oh, S. C. (2016) · BioMed Research International · doi:10.1155/2016/7590245 · Cited by 23
Brijwani, N., Jain, M., Dhandapani, M., Zahed, F., Mukhopadhyay, P., Biswas, M., Khatri, D., Radhakrishna, V. D., Majumder, B., Radhakrishnan, P., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01566-x · Cited by 23
Functional characterisation of a novel class of in-frame insertion variants of KRAS and HRAS
Eijkelenboom, A., van Schaik, F. M. A., van Es, R. M., Broek, R. W. T., Rinne, T., van der Vleuten, C., Flucke, U. E., Ligtenberg, M. J. L., & Rehmann, H. (2019) · Scientific Reports · doi:10.1038/s41598-019-44584-7 · Cited by 23
Erve, I. V. ’., Wesdorp, N. J., Medina, J. E., Ferreira, L., Leal, A., Huiskens, J., Bolhuis, K., van Waesberghe, J. T. M., Swijnenburg, R., van den Broek, D. A., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00223 · Cited by 23
Prognostic and predictive value of KRAS mutation number in metastatic colorectal cancer
Uçar, G., Ergün, Y., Esen, S. A., Açıkgöz, Y., Dirikoç, M., Esen, İ., Bal, Ö., & Uncu, D. (2020) · Medicine · doi:10.1097/md.0000000000022407 · Cited by 24
Lee, H., Son, E., Lee, K., Lee, Y., Kim, Y., Lee, J.-C., Lim, Y., Hur, M., Kim, D., & Nam, D.-H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235894 · Cited by 22
Molecular genetic profiling of small cell lung carcinoma in a Chinese cohort
Wang, Z., Jiang, Z., & Lu, H. (2019) · Translational Cancer Research · doi:10.21037/tcr.2019.01.26 · Cited by 22
Rhaiem, R., Rached, L. J., Tashkandi, A., Bouché, O., & Kianmanesh, R. (2022) · Cancers · doi:10.3390/cancers14030816 · Cited by 22
Personalized treatment for colorectal cancer: novel developments and putative therapeutic strategies
Akkad, J., Bochum, S., & Martens, U. M. (2015) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-015-1276-0 · Cited by 22
Bonetti, L. R., Barresi, V., Bettelli, S. R., Caprera, C., Manfredini, S., & Maiorana, A. (2016) · Human Pathology · doi:10.1016/j.humpath.2016.12.011 · Cited by 22
Supplementary Materials and Methods
Groenendijk, F. H., Zwart, W. T., Floore, A. N., Akbari, S., & Bernards, R. (2013) · Cited by 22
EGFR inhibits TNF-α-mediated pathway by phosphorylating TNFR1 at tyrosine 360 and 401
Nam, Y. W., Shin, J.-H., Kim, S., Hwang, C. H., Lee, C.-S., Hwang, G., Kim, H.-R., Roe, J., & Song, J. (2024) · Cell Death and Differentiation · doi:10.1038/s41418-024-01316-3 · Cited by 23
Hyman, D. M., Snyder, A., Carvajal, R. D., Gerecitano, J. F., Voss, M. H., Ho, A. L., Konner, J. A., Winkelmann, J. L., Stasi, M. A., Monson, K. R., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2693-z · Cited by 21
Ma, B. B. Y., Mo, F. K. F., TONG, J. H. M., Wong, C. Y., Wong, S. C. C., Ho, W. M., Wu, Ç., Lam, P. W., Chan, K.-F., Chan, T. S. K., et al. (2015) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12342 · Cited by 20
Melloni, G. E. M., de Pretis, S., Riva, L., Pelizzola, M., Ceol, A. G. M., Costanza, J., Müller, H., & Zammataro, L. A. (2016) · BMC Bioinformatics · doi:10.1186/s12859-016-0935-7 · Cited by 19
Characterization of novel low passage primary and metastatic colorectal cancer cell lines
Boot, A., van Eendenburg, J., Crobach, S., Ruano, D., Speetjens, F. M., Calame, J. J., Oosting, J., Morreau, H. M., & van Wezel, T. (2016) · Oncotarget · doi:10.18632/oncotarget.7391 · Cited by 19
Zhang, X., Ran, W., Wu, J., Li, H., Liu, H., Wang, L., Xiao, Y., Wang, X., Li, Y., & Xing, X. (2018) · PeerJ · doi:10.7717/peerj.4341 · Cited by 20
The extended spectrum of RAS‐MAPK pathway mutations in colorectal cancer
Costigan, D. C., & Dong, F. (2019) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22813 · Cited by 21
Queralt, B., Cuyàs, E., Bosch‐Barrera, J., Massaguer, A., Llorens, R., Martı́n-Castillo, B., Brunet, J., Salazar, R., & Menéndez, J. A. (2016) · Oncotarget · doi:10.18632/oncotarget.11985 · Cited by 19
Exon-4 Mutations in KRAS Affect MEK/ERK and PI3K/AKT Signaling in Human Multiple Myeloma Cell Lines
Weißbach, S., Heredia-Guerrero, S. C., Barnsteiner, S., Großhans, L., Bodem, J., Starz, H., Langer, C., Appenzeller, S., Knop, S. T., Steinbrunn, T., et al. (2020) · Cancers · doi:10.3390/cancers12020455 · Cited by 18
FMS‐like tyrosine kinase 3 (FLT3) amplification in patients with metastatic colorectal cancer
Hasegawa, H., Taniguchi, H., Nakamura, Y., Kato, T., Fujii, S., Ebi, H., Shiozawa, M., Yuki, S., Masuishi, T., Kato, K., et al. (2020) · Cancer Science · doi:10.1111/cas.14693 · Cited by 18
Allievi, N., Sidhom, M., Samuel, M. V., Tzivanakis, A., Dayal, S., Cecil, T. D., Mohamed, F., & Moran, B. (2024) · Annals of Surgical Oncology · doi:10.1245/s10434-024-15942-1 · Cited by 18
Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories
Cheng, L., Ren, W., Xie, L., Li, M., Liu, J., Hu, J. Y., Liu, B., & Qian, X. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2489-6 · Cited by 18
Otmani, I. E., Agy, F. E., Baradai, S. E., Bouguenouch, L., Lahmidani, N., Abkari, M. E., Benajah, D., Toughrai, İ., Bouhaddouti, H. E., Mouaqit, O., et al. (2020) · Disease Markers · doi:10.1155/2020/8459303 · Cited by 18
Saadat, L. V., Boerner, T., Goldman, D. A., Gönen, M., Frankel, T. L., Vakiani, E., Kingham, T. P., Jarnagin, W. R., Wei, A. C.-C., Soares, K. C., et al. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08862-3 · Cited by 18
Self-citationRegulation of homeostasis and oncogenesis in the intestinal epithelium by Ras
Velho, S., & Haigis, K. M. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.06.002 · Cited by 18
Miniaturized Real-Time PCR on a Q3 System for Rapid KRAS Genotyping
Guarnaccia, M., Iemmolo, R., Petralia, S., Sabrina Conoci, A., & Cavallaro, S. (2017) · Sensors · doi:10.3390/s17040831 · Cited by 17
Kato, J., Futamura, M., Kanematsu, M., Gaowa, S., Mori, R., Tanahashi, T., Matsuhashi, N., & Yoshida, K. (2015) · International Journal of Cancer · doi:10.1002/ijc.29881 · Cited by 17
XD, C. Z. T. (2014) · Journal of Molecular and Genetic Medicine · doi:10.4172/1747-0862.1000145 · Cited by 18
Lorentzen, J. A., Grzyb, K., Angelis, P. M. D., Hoff, G. S., Eide, T. J., & Andresen, P. A. (2016) · Clinical Medicine Insights Pathology · doi:10.4137/cpath.s40143 · Cited by 17
Smith, J. C., Brooks, L., Hoff, P. M., McWalter, G., Dearden, S. P., Morgan, S. R., Wilson, D. M., Robertson, J. D., & Jürgensmeier, J. M. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.02.023 · Cited by 16
Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants
Post, J. B., Roodhart, J. M. L., & Snippert, H. J. G. (2020) · Trends in cancer · doi:10.1016/j.trecan.2019.12.005 · Cited by 16
Clinical profiling of MRD48 and functional characterization of two novel pathogenic RAC1 variants
Priolo, M., Zara, E., Radio, F. C., Ciolfi, A., Spadaro, F., Bellacchio, E., Mancini, C., Pantaleoni, F., Cordeddu, V., Chiriatti, L., et al. (2023) · European Journal of Human Genetics · doi:10.1038/s41431-023-01351-7 · Cited by 15
Metro, G., Valtorta, E., Siggillino, A., Lauricella, C., Cenci, M., Ludovini, V., Minenza, E., Prosperi, E., Ricciuti, B., Rebonato, A., et al. (2015) · ecancermedicalscience · doi:10.3332/ecancer.2015.559 · Cited by 16
Niya, M. H. K., Basi, A., koochak, A., Tameshkel, F. S., Rakhshani, N., Zamani, F., Imanzade, F., Rezvani, H., Adib-Sereshki, M. M., & Sohrabi, M. (2016) · Europe PMC (PubMed Central) · doi:10.22034/apjcp.2016.17.12.5147 · Cited by 15
McDonell, L. M., Leung, G. K. C., Daoud, H., Ip, J., Chim, S., Luk, H., Lan, L. C. L., Boycott, K. M., & Chung, B. H. (2018) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.40349 · Cited by 14
The Evolutionary Landscape of Colorectal Tumorigenesis: Recent Paradigms, Models, and Hypotheses
van Ginkel, J. Q., Tomlinson, I. P. M., & Soriano, I. (2023) · Gastroenterology · doi:10.1053/j.gastro.2022.11.049 · Cited by 14
Novel KRAS Gene Mutations in Sporadic Colorectal Cancer
Naser, W. M., Shawarby, M. A., Al-Tamimi, D. M., Seth, A. K., Al-Quorain, A. A., Nemer, A. M. A., & Albagha, O. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113350 · Cited by 13
Maletzki, C., Hühns, M., Bauer, I., Ripperger, T., Mork, M. M., Vilar, E., Klöcking, S., Zettl, H., Prall, F., & Linnebacher, M. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22632 · Cited by 14
Smyth, L. M., Monson, K. R., Jhaveri, K. L., Drilon, A. E. D. C., Li, B. T., Abida, W. M., Iyer, G., Gerecitano, J. F., Gounder, M. M., Harding, J. J., et al. (2017) · Investigational New Drugs · doi:10.1007/s10637-017-0445-0 · Cited by 14
Cuyàs, E., Queralt, B., Martı́n-Castillo, B., Bosch‐Barrera, J., & Menéndez, J. A. (2017) · Oncology Reports · doi:10.3892/or.2017.5682 · Cited by 14
Prognostic value of specific KRAS mutations in patients with colorectal peritoneal metastases
Tonello, M., Baratti, D., Sammartino, P., Giorgio, A. D., Robella, M., Sassaroli, C., Framarini, M., Valle, M., Macrì, A., Graziosi, L., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102976 · Cited by 13
Campos-Gómez, S., Lara-Guerra, H., Routbort, M. J., Lu, X. Y., & Simon, G. R. (2015) · The International Journal of Biological Markers · doi:10.5301/jbm.5000127 · Cited by 14
Arabzadeh, A., McGregor, K., Breton, V., Kraak, L. V. D., Akavia, U. D., Greenwood, C. M. T., & Beauchemin, N. (2017) · Oncotarget · doi:10.18632/oncotarget.22236 · Cited by 13
Steele, C. W., Whittle, T., & Smith, J. J. (2019) · Chinese Clinical Oncology · doi:10.21037/cco.2019.08.16 · Cited by 13
Cornejo, K. M., Cosar, E. F., Paner, G. P., Yang, P., Tomaszewicz, K., Meng, X., Mehta, V., Sirintrapun, S. J., Barkan, G. A., & Hutchinson, L. (2019) · International Journal of Surgical Pathology · doi:10.1177/1066896919872535 · Cited by 13
Prognostic Value of KRAS Exon 3 and Exon 4 Mutations in Colorectal Cancer Patients
Guo, T., Wu, Y., Huang, D. A., Jin, Y., Sheng, W., Cai, S., Zhou, X., Zhu, X., Liu, F., & Xu, Y. (2021) · Journal of Cancer · doi:10.7150/jca.59193 · Cited by 13
Kang, M. H., Moon, S. U., Sung, J. H., Kim, J. W., Lee, K. W., Lee, H. S., Lee, J. S., & Kim, J. H. (2015) · Cancer Research and Treatment · doi:10.4143/crt.2014.260 · Cited by 13
Montagnani, V., Benelli, M., Apollo, A., Pescucci, C., Licastro, D., Urso, C., Gerlini, G., Borgognoni, L., Luzzatto, L., & Stecca, B. A. (2016) · Oncotarget · doi:10.18632/oncotarget.8758 · Cited by 16
Identification of lysine methylation in the core GTPase domain by GoMADScan
Yoshino, H., Yin, G., Kawaguchi, R. K., Popov, K. I., Temple, B. R. S., Sasaki, M., Kofuji, S., Wolfe, K., Kofuji, K., Okumura, K., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219436 · Cited by 13
Differences in gynecologic tumor development in Amhr2-Cre mice with KRASG12D or KRASG12V mutations
Kun, E., Tsang, Y. T. M., Lin, S., Pan, S., Medapalli, T., Malpica, A. L., Richards, J. S., Gershenson, D. M., & Wong, K. (2020) · Scientific Reports · doi:10.1038/s41598-020-77666-y · Cited by 11
Tripathi, S., Dsouza, N. R., Mathison, A., Leverence, E. N., Urrutia, R. A., & Zimmermann, M. T. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.12.007 · Cited by 11
Genetic Landscape and Its Prognostic Impact in Children With Langerhans Cell Histiocytosis
Wang, C., Cui, L., Li, S., Ma, H., Wang, D., Lian, H., Zhao, Y., Zhang, L.-P., Li, W., Zhang, Q., et al. (2024) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2023-0236-oa · Cited by 11
McNew, K. L., Whipple, W. J., Mehta, A. K., Grant, T. J., Ray, L. C., Kenny, C. J., & Singh, A. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0173 · Cited by 12
Animal Models and Their Role in Imaging-Assisted Co-Clinical Trials
Peehl, D. M., Badea, C. T., Chenevert, T. L., Daldrup-Link, H. E., Ding, L., Dobrolecki, L. E., Houghton, A. M., Kinahan, P. E., Kurhanewicz, J. V., Lewis, M. T., et al. (2023) · Tomography · doi:10.3390/tomography9020053 · Cited by 11
Seol, Y. M., Kwon, C. H., Lee, S. J., Lee, S., Choi, Y., Choi, Y. J., Kim, H., & Park, D. Y. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.10.011 · Cited by 10
Guilfoyle, A. P., Deshpande, C. N., Schenk, G., Maher, M. J., & Jormakka, M. (2014) · Bioscience Reports · doi:10.1042/bsr20140152 · Cited by 11
Kwon, J. J., Dilly, J., Liu, S., Kim, E., Bian, Y., Dharmaiah, S., Tran, T. H., Kapner, K. S., Ly, S. H., Yang, X., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.22.618529 · Cited by 13
Phenotypic characterization of the novel, non‑hotspot oncogenic KRAS mutants E31D and E63K
Angeles, A. K., Yu, R. T. D., la Paz, E. C.-D., & Garcia, R. L. (2019) · Oncology Letters · doi:10.3892/ol.2019.10325 · Cited by 9
Atypical RAS Mutations in Metastatic Colorectal Cancer
Pietrantonio, F., Yaeger, R., Schrock, A. B., Randon, G., Romero-Cordoba, S. L., Rossini, D., Fucà, G., Ross, J. S., Kotani, D., Madison, R., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00136 · Cited by 9
Saridaki, Z., Sagaert, X., de Vriendt, V., Hatzidaki, D., Palmans, S., Smedt, L. D., Hertogh, G. D., & Tejpar, S. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.307 · Cited by 9
Hurtado, C., Encina, G., Wielandt, A. M., Zárate, A. J., Castro, M., Katya Carrillo, G., Kronberg, U., & López-Köstner, F. (2014) · Revista médica de Chile · doi:10.4067/s0034-98872014001100007 · Cited by 9
Metadata
- Authors
- Janakiraman, M., Vakiani, E., Zeng, Z., Pratilas, C. A., Taylor, B. S., Chitale, D., Halilovic, E., Wilson, M., Huberman, K., Ricarte Filho, J. C., Persaud, Y., Levine, D. A., Fagin, J. A., Jhanwar, S. C., Mariadason, J. M., Lash, A., Ladanyi, M., Saltz, L. B., Heguy, A., Paty, P. B., & Solit, D. B.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Authors' Affiliations: 1Human Oncology and Pathogenesis Program and the Departments of 2Pathology, 3Surgery, 4Pediatrics, 5Computational Biology, 6Molecular Pharmacology and Chemistry, and 7Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York; and 8The Ludwig Institute for Cancer Research, Melbourne, Australia
- ORCID
- Venue
- Cancer Research
- Published
- 2010-07-14
- Volume
- 70
- Issue
- 14
- Pages
- 5901-5911
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC2943514
- OpenAlex
- W2125592514
- Cited by
- 290
- References
- 53
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 14 · 2023: 14 · 2022: 11 · 2021: 11 · 2020: 15 · 2019: 18 · 2018: 18 · 2017: 21 · 2016: 22 · 2015: 35 · 2014: 34 · 2013: 23 · 2012: 16
- FWCI
- 8.20
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA127240, P30CA008748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- colorectal cancer, anti-EGFR therapy resistance, predictive biomarkers, gene copy number, prognostic value, solid tumors, KRAS testing
- MeSH terms
- Adenocarcinoma, Animals, Benzamides, Diphenylamine, Exons, Genotype, Humans, Mice, Inbred BALB C, Mice, Nude, Mutation, Proto-Oncogene Proteins, Genes, ras, Mass Spectrometry, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Mutagenesis, Site-Directed, ras Proteins, Mitogen-Activated Protein Kinases, Cell Line, Tumor, Mice, Comparative Genomic Hybridization, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
